Microbiome therapeutics represent a new frontier in the field of medicine. Currently, there are many probiotics, prebiotics, and medical foods and supplements that are commercially available, and several drug / therapy candidates that claim to be capable of modifying / manipulating the microbiome in order to provide therapeutic benefits. The ‘Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017-2030’ report provides a comprehensive study on the current landscape and the future outlook of the growing pipeline of products (therapeutics and diagnostics) in this area. Mentioned below are a few key takeaways from the report.
Key Development Areas
Three major classes of therapeutic products are under development; most of these are early stage efforts and spread across the globe
A Robust, Steadily Growing Pipeline
Microbiome therapeutics have demonstrated the potential to target a range of therapeutic areas; inflammatory and GI disorders are amongst the prime focus areas
US and EU: The Key Innovation Hubs
The US has emerged as a major hub for microbiome based R&D; however, these therapies are likely to be adopted faster in the EU
Growing Partnerships, Indicative of a Lucrative Future Potential
Several partnerships, primarily to support R&D activities, have been inked between industry stakeholders over the past few years
Extensive Venture Capital Support
Start-ups, driven by investment activity from both private and public investors, are expected to continue to spearhead the innovation in this domain
A Significant Future Growth Potential…
Backed by a Robust Pipeline, the Market is Poised to Revolutionize the Treatment of a Myriad of Clinical Conditions and Witness Remarkable Growth in the Long Term
… Well-Distributed Across Therapeutic Areas and Companies
Driven by promising initiatives, the overall opportunity is likely to be well distributed across multiple therapeutic areas and stakeholders
Start-ups to Watch Out For (Indicative List):
Axial Biotherapeutics, Azitra, ClostraBio, Evelo Biosciences, HOST Therabiomics, MicroViable Therapeutics and Siolta Therapeutics. In addition, this domain has witnessed the establishment of several university spin-offs; examples include (in alphabetical order), A-mansia (University catholique de Louvain and Wageningen University), Nubiyota (University of Guelph) and Symberix (University of North Carolina).
To learn more, please click here. For any queries / suggestions or if you’d like to get access to the full research results, please do not hesitate to contact us at firstname.lastname@example.org.